Pharmacotherapeutics of SARS-CoV-2 Infections

J Neuroimmune Pharmacol. 2021 Mar;16(1):12-37. doi: 10.1007/s11481-020-09968-x. Epub 2021 Jan 6.

Abstract

The COVID-19 pandemic has affected more than 38 million people world-wide by person to person transmission of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Therapeutic and preventative strategies for SARS-CoV-2 remains a significant challenge. Within the past several months, effective treatment options have emerged and now include repurposed antivirals, corticosteroids and virus-specific antibodies. The latter has included convalescence plasma and monoclonal antibodies. Complete viral eradication will be achieved through an effective, safe and preventative vaccine. To now provide a comprehensive summary for each of the pharmacotherapeutics and preventative strategies being offered or soon to be developed for SARS-CoV-2.

Keywords: Antibodies; Antivirals; COVID-19 therapeutics; SARS-CoV-2; Vaccine.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Antibodies, Viral / therapeutic use
  • Antiviral Agents / pharmacology
  • COVID-19 / prevention & control
  • COVID-19 / transmission
  • COVID-19 Drug Treatment*
  • COVID-19 Vaccines
  • Drug Repositioning
  • Humans

Substances

  • Antibodies, Viral
  • Antiviral Agents
  • COVID-19 Vaccines